Benzinga · Aug 17, 2026
CEL-SCI Q3 EPS $(0.47) Up From $(1.36) YoY
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.47) per share. This is a 65.44 percent increase over losses of $(1.36) per share from the same period last year.
CV
AMEX · CVM
CEL-SCI Corporation
Healthcare · Biotechnology
$1.48
Up+$0.01 (+0.68%)
Updated Sep 16, 2026, 7:17 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 44.87M
- P/E ratio
- -1.07
- Dividend yield
- 0.00%
- 52-week range
- $0.89 – $4.95
- Volume
- 95.5K
- Avg. volume
- 93.07K
Price performance
CVM price history
1M range · 20 trading sessions · Daily adjusted prices
CVM closed at $1.48 after 20 trading sessions, down 6.92% for the selected period.
- Last close
- $1.48
- Period change
- -6.92%
- Period low
- $1.38
- Period high
- $1.65
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1.53 | $1.54 | $1.47 | $1.48 | 95.5K |
| Sep 14, 2026 | $1.46 | $1.56 | $1.46 | $1.52 | 66.54K |
| Sep 11, 2026 | $1.55 | $1.55 | $1.46 | $1.49 | 98.52K |
| Sep 10, 2026 | $1.57 | $1.58 | $1.51 | $1.52 | 75.96K |
| Sep 9, 2026 | $1.67 | $1.67 | $1.54 | $1.54 | 85.82K |
| Sep 8, 2026 | $1.64 | $1.765 | $1.64 | $1.65 | 283.88K |
| Sep 4, 2026 | $1.61 | $1.63 | $1.58 | $1.63 | 75.07K |
| Sep 3, 2026 | $1.65 | $1.6792 | $1.6041 | $1.61 | 117.06K |
| Sep 2, 2026 | $1.64 | $1.701 | $1.60 | $1.65 | 134.71K |
| Sep 1, 2026 | $1.60 | $1.6312 | $1.565 | $1.61 | 70.26K |
| Aug 31, 2026 | $1.59 | $1.62 | $1.54 | $1.62 | 56.39K |
| Aug 28, 2026 | $1.61 | $1.61 | $1.525 | $1.56 | 170.34K |
| Aug 27, 2026 | $1.60 | $1.69 | $1.565 | $1.60 | 161.62K |
| Aug 26, 2026 | $1.55 | $1.70 | $1.525 | $1.61 | 263.05K |
| Aug 25, 2026 | $1.40 | $1.4999 | $1.3701 | $1.48 | 86.44K |
| Aug 24, 2026 | $1.42 | $1.43 | $1.34 | $1.38 | 149.14K |
| Aug 21, 2026 | $1.48 | $1.49 | $1.42 | $1.42 | 66.14K |
| Aug 20, 2026 | $1.62 | $1.64 | $1.45 | $1.46 | 183.5K |
| Aug 19, 2026 | $1.61 | $1.69 | $1.59 | $1.64 | 184.79K |
| Aug 18, 2026 | $1.57 | $1.675 | $1.55 | $1.59 | 228.79K |
Latest CVM news
The latest Smart Investors Daily articles mentioning CVM.
Stock researchCompany · Overview
CVM research
Overview
Company profile and research snapshot.
Company profile
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 12, 2023 | EF Hutton | Buy | — |
| Mar 9, 2023 | EF Hutton | Buy | — |
| Dec 29, 2022 | EF Hutton | Buy | — |
| Apr 7, 2022 | EF Hutton | Buy | — |
| Jan 13, 2020 | H.C. Wainwright | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 4, 2026
CEL-SCI Announces Publication Of Its Study, 'A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival In Oral Cancer Patients With Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role Of Tumor PD-L1 Expression' In Journal Oral Oncology
The published article identified low and zero (0%) PD-L1 expression and no lymph node involvement as biomarkers for selecting patients most likely to benefit from Multikine pre-surgery treatmentStudy concludes Multikine
Yahoo · Jul 13, 2026
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
VIENNA, Va., July 13, 2026--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer.
Benzinga · Jul 13, 2026
CEL-SCI To Launch Phase 3 Confirmatory Study
Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South AmericaThe 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
